Topical bimatoprost for the treatment of eyebrow hypotrichosis.

11:40 EDT 31st October 2014 | BioPortfolio

Summary of "Topical bimatoprost for the treatment of eyebrow hypotrichosis."

Topical bimatoprost was FDA approved in December of 2008 for the treatment of eyelash hypotrichosis. Since its approval, some physicians have advocated the use of bimatoprost "off label" for hair growth in other areas, such as the scalp or eyebrows, but there has yet to be published scientific evidence to support this use. We report one of the first cases of significant eyebrow hair growth in a patient after use of topical bimatoprost for eyebrow hypotrichosis. J Drugs Dermatol. 2012;11(1):106-108.

Affiliation

Journal Details

This article was published in the following journal.

Name: Journal of drugs in dermatology : JDD
ISSN: 1545-9616
Pages: 106-8

Links

PubMed Articles [16375 Associated PubMed Articles listed on BioPortfolio]

Application of bimatoprost ophthalmic solution 0.03% for the treatment of eyebrow hypotrichosis: series of ten cases.

In December 2008, bimatoprost ophthalmic solution 0.03% was approved in the United States for the treatment of hypotrichosis of the eyelashes. Since then, there have been several reports in the litera...

Periorbital muscle atrophy associated with topical bimatoprost therapy.

Topical Bimatoprost is a common and popular prostaglandin analog used as an ocular hypotensive agent in the treatment of glaucoma. Side effects include ocular hyperaemia, ocular pruritus, and periocul...

A Retrospective Review and Observational Study of Outcomes and Safety of Bimatoprost Ophthalmic Solution 0.03% for Treating Eyelash Hypotrichosis.

The efficacy and safety of bimatoprost ophthalmic solution 0.03% for treating hypotrichosis were shown in a randomized controlled trial and in an open-label study. To date, no data on real-world exper...

Bimatoprost 0.01% vs bimatoprost 0.03%: a 12-month prospective trial of clinical and in vivo confocal microscopy in glaucoma patients.

PurposeTo evaluate the safety of two commercially available formulations of bimatoprost eye drops: 0.03 and 0.01% ophthalmic solutions.MethodsThis was a randomized, prospective, parallel-group, open-l...

Optimizing the Use of Topical Agents in Psoriasis.

The vast majority of patients with psoriasis have localized disease that is manageable by topical therapy alone, and patients with more severe disease still require topical treatment for plaques that ...

Clinical Trials [839 Associated Clinical Trials listed on BioPortfolio]

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

This one-year study evaluates the long-term safety and effectiveness of bimatoprost solution application to the eyelid margin (where the eyelashes meet the skin) to treat hypotrichosis of ...

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasin...

Safety and Efficacy of Bimatoprost Solution in Treating Chemotherapy-induced Eyelash Loss or Hypotrichosis in Children

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily application to the upper eyelid margins compared with vehicle in treating eyelash loss or hypotric...

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

RATIONALE: Bimatoprost ophthalmic solution may help increase eyebrow and eyelash growth in patients who have undergone chemotherapy. PURPOSE: This randomized clinical trial is studying ho...

Minoxidil 1% for Eyebrow Enhancement

The purpose of the study is to compare efficacy and safety of minoxidil 1% versus placebo in enhancement of eyebrows.

Medical and Biotech [MESH] Definitions

Rare autosomal dominant disorder of the hair shaft. The clinical features of the disease include HYPOTRICHOSIS, dry, and/or brittle hair, with varying degrees of ALOPECIA. Mutations in the hair-specific keratin genes KRTHB1, KRTHB3, or KRTHB6 are associated with monilethrix. Autosomal recessive monilethrix with limited HYPOTRICHOSIS are also known. Mutations in Dsg4, Liph, and P2ry5 protein genes are associated with the recessive form of monilethrix.

A topical glucocorticoid used in the treatment of ECZEMA.

A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.

Fluorides, usually in pastes or gels, used for topical application to reduce the incidence of DENTAL CARIES.

Presence of less than the normal amount of hair. (Dorland, 27th ed)

Search BioPortfolio:
Loading